Aptahem AB (publ) (NGM:APTA)
0.3490
+0.0270 (8.39%)
At close: Sep 30, 2026
Aptahem AB Employees
Aptahem AB had 3 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year. That makes Aptahem AB the 43,311th largest employer in the world and 757th in Sweden.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-1.95M SEK
Market Cap
9.05M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 3 | 0 | - |
| Mar 31, 2026 | 3 | -2 | -37.50% |
| Dec 31, 2025 | 3 | -1 | -25.00% |
| Sep 30, 2025 | 3 | -2 | -37.50% |
| Jun 30, 2025 | 3 | -3 | -50.00% |
| Mar 31, 2025 | 4 | -1 | -20.00% |
| Dec 31, 2024 | 4 | 0 | - |
| Sep 30, 2024 | 4 | -1 | -20.00% |
| Jun 30, 2024 | 5 | 0 | - |
| Mar 31, 2024 | 5 | -1 | -16.67% |
| Dec 31, 2023 | 4 | -1 | -20.00% |
| Sep 30, 2023 | 5 | -1 | -16.67% |
| Jun 30, 2023 | 5 | 0 | - |
| Mar 31, 2023 | 6 | 0 | - |
| Dec 31, 2022 | 5 | 1 | 25.00% |
| Sep 30, 2022 | 6 | 1 | 20.00% |
| Jun 30, 2022 | 5 | 0 | - |
| Mar 31, 2022 | 6 | 0 | 7.14% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Magle Chemoswed Holding AB | 150 |
| Nanologica AB | 72 |
| NextCell Pharma AB | 24 |
| ExpreS2ion Biotech Holding AB | 19 |
| Alligator Bioscience AB | 11 |
| Fluicell AB | 11 |
| AcouSort AB | 11 |
| Spago Nanomedical AB | 6 |
Aptahem AB News
- 2 months ago - Aptahem AB Quarterly report: Q2 2026 - Filings
- 5 months ago - Aptahem AB Quarterly report: Q1 2026 - Filings
- 8 months ago - Aptahem AB Annual report: Q4 2025 - Filings
- 8 months ago - Aptahem AB Quarterly report: Q4 2025 - Filings
- 11 months ago - Aptahem AB Quarterly report: Q3 2025 - Filings